Ascendia Pharmaceuticals has filed a notice of an exempt offering of securities to raise $4,084,536.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Ascendia Pharmaceuticals is raising up to $4,084,536.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Ascendia Pharmaceuticals
Ascendia Pharmaceuticals, now operating as Ascendia Pharmaceutical Solutions, is a specialty contract development and manufacturing organization (CDMO) based in North Brunswick, New Jersey. The company provides comprehensive solutions that support drug development from pre-formulation through commercialization. Its services include formulation development, cGMP manufacturing, and ICH stability studies, along with proprietary nanotechnology platforms designed to solve difficult drug delivery challenges. The website also highlights that Ascendia serves pharmaceutical and biological companies and describes itself as a partner of choice for these clients. A notable point on the page is its claim of having been a leading specialty pharma CDMO for over a decade and of making the Impossible Possible.
To learn more, visit https://www.ascendiacdmo.com/
LinkedIn: https://www.linkedin.com/company/ascendia-pharmaceutical-solutions-llc
Contact:
Michael Bogda, Executive Director
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.